MiR‐1827 functions as a tumor suppressor in lung adenocarcinoma by targeting MYC and FAM83F
- 8 October 2019
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 121 (2) , 1675-1689
Abstract
The bioactivity of microRNA‐1827 (miR‐1827) in lung adenocarcinoma cells would be explored. The expression level of gene and miR‐1827 in 76 pairs of lung adenocarcinoma tissues and adjacent counterparts were analyzed by a quantitative real‐time polymerase chain reaction. Primary lung adenocarcinoma cells were derived from patients’ tissues. These cells were treated with miR‐1827 agomir to mimic the upregulation of endogenous miR‐1827. The malignant degree of lung adenocarcinoma cells in vitro was evaluated by cell proliferation, colony formation, transwell invasion, and apoptosis assays. Western blot analysis was used to observe the transition of lung adenocarcinoma cells from epithelial‐to‐mesenchymal. Target genes of miR‐1827 were predicted by bioinformatics analysis. In addition, the interaction between miR‐1827 and candidate messenger RNAs was verified by dual‐luciferase reporter assay and AGO2‐RNA immunoprecipitation. Besides, the effect of miR‐1827 on tumors was verified by in vivo experiments. Transient gene overexpression was achieved by plasmids transfection. In this study, we found that the expression of miR‐1827 was downregulated in lung adenocarcinoma, and its low expression was significantly correlated with the progression of lung adenocarcinoma and poor prognosis of patients. miR‐1827 overexpression remarkably reduced the malignancy of primary lung adenocarcinoma cells in vitro. MYC and FAM83F were identified as two targeted genes of miR‐1827 in lung adenocarcinoma cells. The levels of these two genes were upregulated in lung adenocarcinoma, and their high expression was significantly associated with the progression of lung adenocarcinoma and poor prognosis of patients. Overexpression of MYC or FAM83F attenuated the effects of miR‐1827 on primary lung adenocarcinoma cells in vitro. In addition, in vivo experiments showed that miR‐1827 inhibited tumor growth by reducing the levels of MYC and FAM83F. In conclusion, miR‐1827 might repress the development of lung adenocarcinoma by targeting oncogenic genes MYC and FAM83F.Keywords
This publication has 25 references indexed in Scilit:
- Non-small-cell lung cancer and miRNAs: novel biomarkers and promising tools for treatmentClinical Science, 2015
- Conserved Oncogenic Behavior of the FAM83 Family Regulates MAPK Signaling in Human CancerMolecular Cancer Research, 2014
- HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinomaMolecular Cancer, 2014
- CRKL promotes lung cancer cell invasion through ERK‐MMP9 pathwayMolecular Carcinogenesis, 2014
- High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancerEuropean Journal of Cancer, 2013
- Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2012
- Overexpression of crkl correlates with poor prognosis and cell proliferation in non‐small cell lung cancerMolecular Carcinogenesis, 2012
- Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non–Small Cell Lung CancersCancer Discovery, 2011
- Genetic Variation in an miRNA-1827 Binding Site in MYCL1 Alters Susceptibility to Small-Cell Lung CancerCancer Research, 2011
- MYC Amplification as a Prognostic Marker of Early-Stage Lung Adenocarcinoma Identified by Whole Genome Copy Number AnalysisClinical Cancer Research, 2011